N/A
Completed N=5
HDtDCS in Logopenic Variant PPA: Effects on Language and Neural Mechanisms
Primary Progressive Aphasia
Source: ClinicalTrials.gov NCT03805659 ↗
Enrolled (actual)
5
Serious AEs
12.5%
Results posted
Jun 2024
Primary outcomePrimary: Determine Changes in Language Performance After Stimulation Sessions
Summary
This study aims to evaluate the effectiveness of a therapy called High-Definition Transcranial Direct Current Stimulation (HD-tDCS) for the treatment of the language deficits experienced by people with a type of Primary Progressive Aphasia. This study uses a combination of brain imaging, language assessment, language training sessions, and HD-tDCS therapy as well as placebo therapy sessions.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Determine Changes in Language Performance After Stimulation Sessions |
— | — |
| SECONDARY Determine the Resting State Language Network-level Changes in Left TPC Functional Connectivity. |
— | — |
| SECONDARY Determine the Neuronal Frequency Distribution and Connectivity Measures Associated With the Left TPC as Assessed by MEG. |
— | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosed with language variant Primary Progressive Aphasia (lvPPA) subtype, defined as either clinical lvPPA or imaging-supported lvPPA in accordance with the most recent diagnostic criteria (Mesulam., 2001; Gorno-Tempini et al., 2011).
- Fluent in English.
- 45 years of age or older.
- Structural brain MRI performed within 3 years prior to enrollment.
Exclusion Criteria
- Severe cognitive, auditory or visual impairments that would preclude cognitive testing.
- Presence of major untreated or unstable psychiatric disease.
- A chronic medical condition that is not treated or is unstable.
- The presence of cardiac stimulators or pacemakers.
- Any metal implants in the skull
- Contraindications to MRI
- History of seizures
- History of dyslexia or other developmental learning disabilities.
Data sourced from ClinicalTrials.gov (NCT03805659). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.